CYTOKINETICS, INCORPORATED Increase (Decrease) in Other Noncurrent Liabilities
CYTOKINETICS, INCORPORATED (CYTK) reported Increase (Decrease) in Other Noncurrent Liabilities of -$7.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was -$3.11M.
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was -$3.95M, a 343.92% decline year-over-year.
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$3.53M, a 1588.61% decline year-over-year.
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was -$2.68M, a 1217.08% decline year-over-year.
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$6.25M.
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$1.36M.
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$9.59M.
- CYTOKINETICS, INCORPORATED increase (decrease) in other noncurrent liabilities for fiscal 2022 was -$4.06M, a 211.21% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$7.07M 10-Q · filed 2026-08-06 | -$10.59M derived: sum of 3 quarters · filed 2026-08-06 | -$13.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.95M 10-Q · filed 2026-05-05 | -$7.48M derived: sum of 2 quarters · filed 2026-05-05 | -$10.16M derived: sum of 3 quarters · filed 2026-05-05 | -$11.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.21M derived: sum of 2 quarters · filed 2026-02-26 | -$7.87M derived: sum of 3 quarters · filed 2026-08-06 | -$6.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$2.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.34M derived: sum of 2 quarters · filed 2026-08-06 | -$2.72M 10-Q · filed 2025-11-05 | -$2.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$41.00K 10-Q · filed 2026-08-06 | $196.00K derived: sum of 3 quarters · filed 2026-08-06 | $436.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.62M 10-Q · filed 2026-05-05 | $1.86M derived: sum of 2 quarters · filed 2026-05-05 | $2.10M derived: sum of 3 quarters · filed 2026-05-05 | $2.20M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $477.00K derived: sum of 2 quarters · filed 2026-02-26 | $579.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | $240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $342.00K derived: sum of 2 quarters · filed 2025-11-05 | -$1.59M 10-Q · filed 2025-11-05 | -$5.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.83M 10-Q · filed 2025-08-07 | -$5.41M derived: sum of 3 quarters · filed 2026-02-26 | -$8.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$1.94M 10-Q · filed 2025-05-06 | -$5.51M derived: sum of 2 quarters · filed 2026-02-26 | -$8.17M derived: sum of 3 quarters · filed 2026-02-26 | -$10.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.24M derived: sum of 2 quarters · filed 2026-02-26 | -$8.88M derived: sum of 3 quarters · filed 2026-02-26 | -$9.59M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$5.30M derived: sum of 2 quarters · filed 2024-11-07 | -$6.01M 10-Q · filed 2024-11-07 | -$6.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$3.35M 10-Q · filed 2024-08-09 | -$3.55M derived: sum of 3 quarters · filed 2025-02-27 | -$3.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$705.00K 10-Q · filed 2024-05-10 | -$908.00K derived: sum of 2 quarters · filed 2025-02-27 | -$1.10M derived: sum of 3 quarters · filed 2025-02-27 | -$3.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$400.00K derived: sum of 2 quarters · filed 2025-02-27 | -$2.39M derived: sum of 3 quarters · filed 2025-02-27 | -$4.06M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$2.19M derived: sum of 2 quarters · filed 2023-11-03 | -$3.85M 10-Q · filed 2023-11-03 | -$5.68M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$3.66M 10-Q · filed 2023-08-03 | -$5.48M derived: sum of 3 quarters · filed 2024-02-28 | -$3.67M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$1.67M 10-Q · filed 2023-05-05 | -$3.49M derived: sum of 2 quarters · filed 2024-02-28 | -$1.68M derived: sum of 3 quarters · filed 2024-02-28 | $1.98M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$9.00K derived: sum of 2 quarters · filed 2024-02-28 | $3.65M derived: sum of 3 quarters · filed 2024-02-28 | $3.65M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $5.47M derived: sum of 2 quarters · filed 2022-11-04 | $5.47M 10-Q · filed 2022-11-04 | $5.47M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $3.66M 10-Q · filed 2022-08-05 | $3.66M derived: sum of 3 quarters · filed 2023-03-01 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |